Cellectis Shareholders Support Management’s Vision
Company Announcements

Cellectis Shareholders Support Management’s Vision

Cellectis SA (CLLS) has released an update.

Cellectis, a biotech firm focused on gene-editing for cancer treatments, reported successful shareholder voting outcomes with nearly half of its stock represented, and all but one management-supported resolutions passed. The meeting’s detailed voting results are accessible on the company’s website. Cellectis continues to develop its innovative CAR-T cell therapies and gene-editing technologies to address critical medical needs.

For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCellectis S.A. Reports Q3 2024 Financial Results and Updates
TipRanks Auto-Generated NewsdeskCellectis SA Advances CAR T-cell Therapy for Solid Tumors
TheFlyCellectis price target lowered to $5 from $7 at Barclays
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App